BrightGene looks to the West as obesity shot nears China approval

Steve Chen, BrigthGene global chief medical officer July 2, 2026 06:48 AM EDT R&DGLP-1 drugs Bright­Gene looks to the West as obe­si­ty shot nears Chi­na ap­proval Elizabeth Cairns Senior biopharma journalist Armed with im­pres­sive Phase 3 da­ta, Bright­Gene is tak­ing its obe­si­ty shot to Chi­nese reg­u­la­tors. It ex­pects tri­al da­ta in the West to be even … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER